India · Delayed Price · Currency is INR Ipca Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw 6.5% revenue growth and improved EBITDA margins, with strong domestic and export performance, especially in chronic therapies and West Africa. Unichem margins remain under pressure but are expected to recover as new launches and filings mature.
-
Domestic and API businesses delivered strong growth, with EBITDA margins improving year-over-year. Export formulations faced headwinds, but guidance for H2 remains positive, and Unichem's performance is recovering. R&D spend will stay elevated as the company builds its global pipeline.
-
Domestic and export businesses delivered double-digit growth, with strong gains in chronic and acute segments. Standalone margins improved, but consolidated EBITDA margin guidance was trimmed due to Unichem's challenges, including one-time provisions and market share losses.
Fiscal Year 2025
-
Domestic and export businesses delivered double-digit growth, with EBITDA margins improving across segments. New manufacturing facilities and ongoing Unichem integration are set to drive future growth, while guidance remains conservative at 8-10% revenue growth and 1% margin expansion for FY26.
-
EBITDA margins and gross margins reached record highs, driven by improved product mix, strong chronic and ROW market growth, and operational efficiencies. Domestic and EU businesses outperformed the market, while Unichem's integration boosted consolidated margins. Net debt is set to be eliminated next year.
-
Domestic and export formulation businesses delivered double-digit growth, with EBITDA margins improving year-over-year due to better product mix and cost controls. Guidance for FY25 margins was raised, while revenue growth was slightly moderated; Unichem integration and US launches are expected to drive future growth.
-
Domestic business drove double-digit growth and market share gains, while exports and API faced headwinds from logistics and supply chain issues. Margins exceeded guidance, and full-year profitability is expected to surpass earlier projections despite a downward revision in revenue growth.